The pharmaceutical haircare market in India has seen remarkable growth, driven by increased awareness and younger patients seeking treatment, with sales surging by 37.1% year-on-year in September 2026.
The pharmaceutical haircare market in India has emerged as a significant growth sector within the broader dermatology landscape, achieving a remarkable year-on-year growth rate of 24.3% and reaching ₹1,287 crore in the moving annual total (MAT) ending September 2026. This growth rate is more than double that of the overall dermatology market, which reported a 10.7% increase during the same period, according to data from PharmaTrac.
Market analysts highlight that the surge in the haircare segment is largely attributed to a combination of factors, including heightened awareness of hair-loss treatments, the introduction of innovative formulations, and a growing demographic of younger patients seeking medical intervention for hair-related issues. In September alone, the sales in the haircare category surged by 37.1% year-on-year, amounting to ₹132.6 crore, whereas the dermatology market overall experienced a slower growth of 14.7%.
Drivers of Growth
Sheetal Sapale, Vice President of Commercial at Pharmarack AWACS, noted the category’s substantial expansion, which has seen a nearly 78% increase over the past four years, rising from ₹724 crore in September 2022 to the current figure of ₹1,287 crore. According to her analysis, the growth was significantly driven by volume increases, contributing 20.5 percentage points to September’s growth, while new product introductions added 9.5 percentage points and price growth accounted for 7.2 percentage points. Additionally, haircare unit sales rose by 18.7% on a MAT basis, indicating that increasing demand is a critical factor beyond just price adjustments.
Market Composition
The market is predominantly influenced by minoxidil-based treatments, which represent a significant portion of the overall haircare sales. Standalone minoxidil products recorded MAT sales of ₹456.5 crore, reflecting a 13.6% growth, while combinations of minoxidil and finasteride experienced a notable 32% increase, reaching ₹315.1 crore. Together, these two categories constitute nearly 60% of haircare sales. Another category, hair restorers, grew by 28.9% to ₹201.3 crore, further illustrating the robust interest in hair-loss treatments.
Sandeep Khandelwal, Chief Executive Officer of Dr. Reddy’s Laboratories for Asia, Africa, Australia, CISUR, and Global Generics India, emphasized that the growth of the haircare market signifies a structural expansion rather than merely an increase in spending by existing patients. He remarked that hair loss is increasingly recognized as a legitimate medical condition, prompting more individuals to consult dermatologists at earlier stages instead of relying solely on cosmetic remedies.
Demographic Shifts and Awareness
Furthermore, Khandelwal pointed to a rising trend among younger adults who are more informed and willing to address hair-loss issues due to improved access to information and growing health consciousness. This demographic shift is creating new opportunities for pharmaceutical companies within the sector. For instance, Dr. Reddy’s Mintop recorded sales of ₹184.7 crore, reflecting an 18.8% year-on-year increase, while its newer product, Mintop Pro, saw an impressive growth rate of 82.5%, reaching ₹20.8 crore. Other notable competitors in the market include Intas Pharmaceuticals’ Morr-F, which expanded by 31.3% to ₹137.5 crore, and Cipla’s Tugain, which reported sales of ₹35 crore, up 2.6%.
Consultation Trends and Patient Mindset
Dr. Smriti Naswa Singh, a consultant dermatologist at Fortis Hospital in Mulund, Mumbai, indicated that the increasing awareness surrounding hair loss has led to more patients seeking medical advice rather than resigning themselves to the condition as inevitable. She noted, “Earlier they would ignore it, thinking that managing hair loss was not possible, but now they approach us for treatment.” Meanwhile, Dr. Ruben Bhasin Passi, a senior consultant in dermatology at CK Birla Hospital, Gurugram, cautioned that increased consultations do not necessarily indicate a rise in hair loss prevalence; rather, better awareness and access to dermatological care could be influencing this trend.
Dr. Singh also highlighted that minoxidil-finasteride combinations are not universally prescribed; rather, they are selectively administered based on patient response to standalone treatments. Additionally, she acknowledged the role of social media in shaping demand, stating that while influencers may raise awareness about hair-loss treatments, they can also foster unrealistic expectations regarding the speed and effectiveness of results.
Dermatologists continue to advise caution against self-medication and emphasize that hair-loss treatments often require several months to yield visible results. As the market for pharmaceutical haircare continues to expand, the interplay between awareness, treatment options, and patient expectations will be critical in shaping its future trajectory.
